epinephrine · Adamis Pharms Corp · NDA 207534
Symjepi
Earliest generic entry, as listed
20 Oct 2036
Blocked by patent: US 11141540.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11141540 | product, use U-3379 | 20 Oct 2036 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 207534 · 001 · RLD | solution, intramuscular, subcutaneous | 0.3MG/0.3ML (0.3MG/0.3ML) | 20 Oct 2036 |
| 207534 · 002 · RLD · discontinued | solution, intramuscular, subcutaneous | 0.15MG/0.3ML (0.15MG/0.3ML) | 20 Oct 2036 |